vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $246.2M, roughly 1.4× HCI Group, Inc.). HCI Group, Inc. runs the higher net margin — 39.7% vs 13.2%, a 26.5% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs -2.7%). HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $87.2M). Over the past eight quarters, HCI Group, Inc.'s revenue compounded faster (9.2% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
HAE vs HCI — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $246.2M |
| Net Profit | $44.7M | $97.7M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 58.5% |
| Net Margin | 13.2% | 39.7% |
| Revenue YoY | -2.7% | 52.1% |
| Net Profit YoY | 19.3% | 3679.2% |
| EPS (diluted) | $0.95 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $246.2M | ||
| Q3 25 | $327.3M | $216.3M | ||
| Q2 25 | $321.4M | $221.9M | ||
| Q1 25 | $330.6M | $216.4M | ||
| Q4 24 | $348.5M | $161.9M | ||
| Q3 24 | $345.5M | $175.3M | ||
| Q2 24 | $336.2M | $206.2M | ||
| Q1 24 | — | $206.6M |
| Q4 25 | $44.7M | $97.7M | ||
| Q3 25 | $38.7M | $65.5M | ||
| Q2 25 | $34.0M | $66.2M | ||
| Q1 25 | $58.0M | $69.7M | ||
| Q4 24 | $37.5M | $2.6M | ||
| Q3 24 | $33.8M | $5.7M | ||
| Q2 24 | $38.4M | $54.1M | ||
| Q1 24 | — | $47.6M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 58.5% | ||
| Q3 25 | 17.9% | 41.9% | ||
| Q2 25 | 16.8% | 42.5% | ||
| Q1 25 | 21.6% | 46.4% | ||
| Q4 24 | 16.9% | 3.6% | ||
| Q3 24 | 15.0% | 8.0% | ||
| Q2 24 | 11.8% | 36.9% | ||
| Q1 24 | — | 37.5% |
| Q4 25 | 13.2% | 39.7% | ||
| Q3 25 | 11.8% | 30.3% | ||
| Q2 25 | 10.6% | 29.8% | ||
| Q1 25 | 17.5% | 32.2% | ||
| Q4 24 | 10.8% | 1.6% | ||
| Q3 24 | 9.8% | 3.2% | ||
| Q2 24 | 11.4% | 26.2% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | $0.95 | $7.29 | ||
| Q3 25 | $0.81 | $4.90 | ||
| Q2 25 | $0.70 | $5.18 | ||
| Q1 25 | $1.17 | $5.35 | ||
| Q4 24 | $0.74 | $0.32 | ||
| Q3 24 | $0.66 | $0.52 | ||
| Q2 24 | $0.74 | $4.24 | ||
| Q1 24 | — | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $1.2B |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $1.0B |
| Total Assets | $2.5B | $2.5B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $1.2B | ||
| Q3 25 | $296.4M | $987.9M | ||
| Q2 25 | $292.9M | $947.2M | ||
| Q1 25 | $306.8M | $754.5M | ||
| Q4 24 | $320.8M | $532.5M | ||
| Q3 24 | $299.3M | $518.8M | ||
| Q2 24 | $344.4M | $445.8M | ||
| Q1 24 | — | $655.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $1.0B | ||
| Q3 25 | $849.2M | $821.8M | ||
| Q2 25 | $882.3M | $758.6M | ||
| Q1 25 | $820.8M | $522.7M | ||
| Q4 24 | $906.9M | $453.3M | ||
| Q3 24 | $878.9M | $455.3M | ||
| Q2 24 | $905.4M | $447.3M | ||
| Q1 24 | — | $395.7M |
| Q4 25 | $2.5B | $2.5B | ||
| Q3 25 | $2.4B | $2.3B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.5B | $2.3B | ||
| Q4 24 | $2.5B | $2.2B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.5B | $1.9B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $444.4M |
| Free Cash FlowOCF − Capex | $87.2M | $440.8M |
| FCF MarginFCF / Revenue | 25.7% | 179.0% |
| Capex IntensityCapex / Revenue | 1.9% | 1.5% |
| Cash ConversionOCF / Net Profit | 2.09× | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $444.4M | ||
| Q3 25 | $111.3M | $26.7M | ||
| Q2 25 | $17.4M | $145.0M | ||
| Q1 25 | $116.6M | $162.0M | ||
| Q4 24 | $43.8M | $331.8M | ||
| Q3 24 | $48.8M | $104.1M | ||
| Q2 24 | $-27.4M | $-29.0M | ||
| Q1 24 | — | $182.0M |
| Q4 25 | $87.2M | $440.8M | ||
| Q3 25 | $106.3M | $25.9M | ||
| Q2 25 | $13.6M | $144.5M | ||
| Q1 25 | $100.9M | $160.3M | ||
| Q4 24 | $35.2M | $327.8M | ||
| Q3 24 | $39.4M | $103.2M | ||
| Q2 24 | $-33.1M | $-30.1M | ||
| Q1 24 | — | $181.0M |
| Q4 25 | 25.7% | 179.0% | ||
| Q3 25 | 32.5% | 12.0% | ||
| Q2 25 | 4.2% | 65.1% | ||
| Q1 25 | 30.5% | 74.1% | ||
| Q4 24 | 10.1% | 202.5% | ||
| Q3 24 | 11.4% | 58.9% | ||
| Q2 24 | -9.8% | -14.6% | ||
| Q1 24 | — | 87.6% |
| Q4 25 | 1.9% | 1.5% | ||
| Q3 25 | 1.5% | 0.4% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 4.7% | 0.8% | ||
| Q4 24 | 2.5% | 2.5% | ||
| Q3 24 | 2.7% | 0.5% | ||
| Q2 24 | 1.7% | 0.5% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | 2.09× | 4.55× | ||
| Q3 25 | 2.88× | 0.41× | ||
| Q2 25 | 0.51× | 2.19× | ||
| Q1 25 | 2.01× | 2.32× | ||
| Q4 24 | 1.17× | 128.41× | ||
| Q3 24 | 1.44× | 18.33× | ||
| Q2 24 | -0.71× | -0.54× | ||
| Q1 24 | — | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
